Interferon beta treatment of multiple sclerosis increases serum interleukin-7

Abstract

Background:

Interleukin-7 (IL-7) is a non-redundant cytokine for T-cell development and survival. The IL-7 signaling pathway has been genetically and functionally associated with several autoimmune diseases including multiple sclerosis (MS).

Objective:

The objective of this paper is to elucidate the effect of the widely used immunomodulatory MS therapy interferon beta (IFNβ) on IL-7 homeostasis.

Methods:

Swedish MS patients were screened for IL-7 concentration in serum and blood cell counts. IL-7 receptor alpha chain (IL-7Rα) expression was determined by semi-quantitative real-time polymerase chain reaction (PCR) and flow cytometry.

Results:

IFNβ treatment led to significantly increased serum IL-7 levels (mean: 17 pg/ml) compared with healthy controls (mean: 7.6 pg/ml) and natalizumab-treated patients (mean: 5.3 pg/ml). In vitro and in vivo, peripheral blood leukocytes showed decreased IL-7Rα expression and IL-7 consumption upon IFNβ exposure, suggesting that their IL-7 responsiveness is impaired during treatment.

Conclusions:

MS patients undergoing IFNβ treatment have increased serum IL-7 levels and decreased IL-7 consumption. Given IL-7’s important role in T-cell immunity, this relationship may be highly relevant for IFNβ’s treatment efficacy.

Keywords

Multiple sclerosis immunology interferon beta natalizumab

Get full access to this article

View all access options for this article.

References

Dyment

Ebers

Sadovnick

. Genetics of multiple sclerosis. Lancet Neurol 2004; 3: 104–110.

Naito

Namerow

Mickey

. Multiple sclerosis: Association with HL-A3. Tissue Antigens 1972; 2: 1–4.

Jersild

Svejgaard

Fog

. HL-A antigens and multiple sclerosis. Lancet 1972; 1: 1240–1241.

Jersild

Fog

Hansen

. Histocompatibility determinants in multiple sclerosis, with special reference to clinical course. Lancet 1973; 2: 1221–1225.

Sawcer

Hellenthal

Pirinen

. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011; 476: 214–219.

Lundström

Greiner

Lundmark

. No influence on disease progression of non-HLA susceptibility genes in MS. J Neuroimmunol 2011; 237: 98–100.

International Multiple Sclerosis Genetics Consortium. Genome-wide association study of severity in multiple sclerosis. Genes Immun 2011; 12: 615–625.

Jensen

Stankovich

Van der Walt

. Multiple sclerosis susceptibility-associated SNPs do not influence disease severity measures in a cohort of Australian MS patients. PLoS One 2010; 5: e10003.

Gregory

Schmidt

Seth

. Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat Genet 2007; 39: 1083–1091.

10.

International Multiple Sclerosis Genetics Consortium, Hafler

Compston

. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007; 357: 851–862.

11.

Lundmark

Duvefelt

Iacobaeus

. Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. Nat Genet 2007; 39: 1108–1113.

12.

Ozenci

Kouwenhoven

Teleshova

. Multiple sclerosis: Pro- and anti-inflammatory cytokines and metalloproteinases are affected differentially by treatment with IFN-beta. J Neuroimmunol 2000; 108: 236–243.

13.

Liu

Pelfrey

Cotleur

. Immunomodulatory effects of interferon beta-1a in multiple sclerosis. J Neuroimmunol 2001; 112: 153–162.

14.

Hemmer

Stuve

Kieseier

. Immune response to immunotherapy: The role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis. Lancet Neurol 2005; 4: 403–412.

15.

Jacobs

Beck

Simon

. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000; 343: 898–904.

16.

Cohen

Oger

Gagnon

. The implications of immunogenicity for protein-based multiple sclerosis therapies. J Neurol Sci 2008; 275: 7–17.

17.

Lundström

Fewkes

Mackall

. IL-7 in human health and disease. Semin Immunol 2012; 24: 218–224.

18.

Bertolotto

Sala

Caldano

. Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta. J Immunol Methods 2007; 321: 19–31.

19.

Jungedal

Lundkvist

Engdahl

. Prevalence of anti-drug antibodies against interferon beta has decreased since routine analysis of neutralizing antibodies became clinical practice. Mult Scler 2012; 18: 1775–1781.

20.

Kawade

. Quantitation of neutralization of interferon by antibody. Methods Enzymol 1986; 119: 558–573.

21.

Fry

Connick

Falloon

. A potential role for interleukin-7 in T-cell homeostasis. Blood 2001; 97: 2983–2990.

22.

Jacobs

O’Malley

Freeman

. Intrathecal interferon reduces exacerbations of multiple sclerosis. Science 1981; 214: 1026–1028.

23.

Arnason

. Interferon beta in multiple sclerosis. Clin Immunol Immunopathol 1996; 81: 1–11.

24.

Ozenci

Kouwenhoven

Huang

. Multiple sclerosis is associated with an imbalance between tumour necrosis factor-alpha (TNF-alpha)- and IL-10-secreting blood cells that is corrected by interferon-beta (IFN-beta) treatment. Clin Exp Immunol 2000; 120: 147–153.

25.

Stone

Frank

Albert

. The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing–remitting multiple sclerosis. Ann Neurol 1995; 37: 611–619.

26.

Sellebjerg

Datta

Larsen

. Gene expression analysis of interferon-beta treatment in multiple sclerosis. Mult Scler 2008; 14: 615–621.

27.

Crawley

Faucher

Angel

. Soluble IL-7R alpha (sCD127) inhibits IL-7 activity and is increased in HIV infection. J Immunol 2010; 184: 4679–4687.

28.

Hoe

McKay

Schibeci

. Functionally significant differences in expression of disease-associated IL-7 receptor alpha haplotypes in CD4 T cells and dendritic cells. J Immunol 2010; 184: 2512–2517.

29.

Lundström

Highfill

Walsh

. Soluble IL7Rα potentiates IL-7 bioactivity and promotes autoimmunity. Proc Natl Acad Sci U S A 2013; 110: E1761–E1770.

30.

Uehira

Matsuda

Nakamura

. Immunologic abnormalities exhibited in IL-7 transgenic mice with dermatitis. J Invest Dermatol 1998; 110: 740–745.

31.

Liu

Leung

Wang

. Crucial role of interleukin-7 in T helper type 17 survival and expansion in autoimmune disease. Nat Med 2010; 16: 191–197.

32.

Rieckmann

O’Connor

Francis

. Haematological effects of interferon-beta-1a (Rebif) therapy in multiple sclerosis. Drug Saf 2004; 27: 745–756.

33.

Francis

Grumser

Alteri

. Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: Incidence and clinical significance. Drug Saf 2003; 26: 815–827.

34.

Napolitano

Grant

Deeks

. Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: Implications for T-cell homeostasis. Nat Med 2001; 7: 73–79.

35.

Malaspina

Moir

Chaitt

. Idiopathic CD4+ T lymphocytopenia is associated with increases in immature/transitional B cells and serum levels of IL-7. Blood 2007; 109: 2086–2088.

36.

Fry

Mackall

. Interleukin-7: Master regulator of peripheral T-cell homeostasis? Trends Immunol 2001; 22: 564–571.

37.

Cimbro

Vassena

Arthos

. IL-7 induces expression and activation of integrin α4β7 promoting naive T-cell homing to the intestinal mucosa. Blood 2012; 120: 2610–2619.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.02 MB